コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ide future vaccine design and antibody-based drug therapy.
2 al fibrillation (AF) to catheter ablation or drug therapy.
3 d as a potential new target for antidiabetic drug therapy.
4 As such they are attractive targets for drug therapy.
5 nderwent ablation, and 99 initially received drug therapy.
6 ic lesions could be important for optimizing drug therapy.
7 ctor of the effectiveness of anti-arrhythmic drug therapy.
8 , and potentially to tailor patient-specific drug therapy.
9 absence of treatment and even more so during drug therapy.
10 f functional interference of ATP6AP2 through drug therapy.
11 tion chemotherapy, or non-platinum-based two-drug therapy.
12 Toxoplasma gondii cyst stage is resistant to drug therapy.
13 ptor proteins and the most common targets of drug therapy.
14 d serve as an ideal target for otoprotective drug therapy.
15 nce the management of patients on antifungal drug therapy.
16 DM) for improving the efficacy and safety of drug therapy.
17 ession is altered by disease development and drug therapy.
18 own about how resistant clones evolve during drug therapy.
19 se receiving an escalation in antiarrhythmic drug therapy.
20 tor (ICD) is frequent despite antiarrhythmic drug therapy.
21 y of an adverse drug reaction resulting from drug therapy.
22 ructure that may represent prime targets for drug therapy.
23 arter of the population, and has no approved drug therapy.
24 f laboratory correlates of human disease and drug therapy.
25 al target class of fundamental importance in drug therapy.
26 derivatives may have potential for glaucoma drug therapy.
27 jor unmet target for a vaccine and antiviral drug therapy.
28 eligible persons could receive sofosbuvir 3-drug therapy.
29 e might represent more tractable targets for drug therapy.
30 a molecular justification for combinatorial drug therapy.
31 ess disease progression and effectiveness of drug therapy.
32 y of nucleoside analogues used in anticancer drug therapy.
33 with loss of Casq2 and test mechanism-based drug therapy.
34 ely to benefit from immediate anti-epileptic drug therapy.
35 dings suggest evaluation of TLR3 agonists in drug therapy.
36 adjuncts to the initiation of antiretroviral drug therapy.
37 an circumvent the immune response and escape drug therapy.
38 hat are essential for the development of new drug therapy.
39 mber aberrations associated with response to drug therapy.
40 ein 78 kDa (GRP78) was utilized for targeted drug therapy.
41 xisting antihyperglycemic and cardiovascular drug therapy.
42 HDCA is a candidate for antiatherosclerotic drug therapy.
43 use in predicting the effects of combination drug therapy.
44 ce/ethnicity, obesity, and immunosuppressive drug therapy.
45 burden longitudinally in living mice during drug therapy.
46 ogy, vaccine development, and antibody-based drug therapy.
47 eases that thus far have been intractable to drug therapy.
48 sential task for the effective monitoring of drug therapy.
49 remains no consensus on how best to monitor drug therapy.
50 ical conditions or occur as a side-effect of drug therapy.
51 atient susceptible to subsequent regimens of drug therapy.
52 echanisms and identify potential targets for drug therapy.
53 predictor of lung utilization regardless of drug therapy.
54 persist in the body through months of multi-drug therapy.
55 specially for applications such as long-term drug therapy.
56 d during the first 56 days of the standard 4-drug therapy.
57 a potential tool to tailor immunosuppressive drug therapy.
58 ry of migraine headaches without hormonal or drug therapy.
59 ound and clinically significant influence on drug therapies.
60 ontinuation of potential trigger factors and drug therapies.
61 ge-guided surgery, and theranostic PEGylated drug therapies.
62 l for further investigation of heart failure drug therapies.
63 and novel molecular targets for anti-cancer drug therapies.
64 ffective antiparkinsonian and antidyskinetic drug therapies.
65 elling and simulation to predict alternative drug therapies.
66 , and aid in the development of new targeted drug therapies.
67 inhibitors and to assess effects of combined drug therapies.
68 among those aged 66 years or older, relevant drug therapies.
69 djunct host-directed cellular and repurposed drug therapies.
70 tudy disease mechanisms as well as potential drug therapies.
71 isease severity and efficacy of vaccines and drug therapies.
72 ns in human serum, that determine dosages in drug therapies.
73 in drug response is a central feature of all drug therapies.
74 ], pyrazinamide, and ethambutol, among other drug therapies.
75 and continues to inspire the search for new drug therapies.
76 to identify physiological changes and future drug therapies.
77 igent tumors that barely respond to standard drug therapies.
78 anipulation through dietary modifications or drug therapies.
79 (OSE), has hampered development of targeted drug therapies.
80 e adverse events were mainly associated with drug therapy (25.6%), surgery (23.7%), diagnosis (12.4%)
81 nosis: (1) drug monotherapy, (2) combination drug therapy, (3) glaucoma procedure, or (4) no claims f
84 total, 83.0% of patients (5120/6172) began a drug therapy (69.5%) or underwent a procedure initially
85 lementing ablation with concurrent liposomal drug therapy, a complete and durable response was obtain
87 odynamic response of portal pressure (PP) to drug therapy accurately stratifies the risk of variceal
88 ing pathway can contribute to development of drug therapy addressing aberrations in that pathway.
89 onal and glial signaling is accomplished via drug therapy/administration, although they frequently fa
92 es of VT control and need for antiarrhythmic drug therapy after endocardial (ENDO) and adjuvant epica
93 or identifying new drugs for multifunctional drug therapy against acute organophosphorus poisoning.
95 for recurrence, is better than conventional drug therapy alone for prevention of postoperative Crohn
96 highlight the progress that has been made in drug therapies and delivery systems, and also cell-based
97 mising biological findings to novel approved drug therapies and discuss the attendant challenges and
98 translational pharmacological studies of new drug therapies and provide evidence for engagement of th
99 COPD) is the primary testing methodology for drug therapies and studies on pathogenic mechanisms of d
100 de insight into the mechanistic link between drug therapies and systems-level off-target effects whil
101 nd a systolic BP threshold for initiation of drug therapy and a therapeutic target of <150 mm Hg in t
102 of biochemical targets has brought to single-drug therapy and creates a statistical and experimental
106 receptors (GPCRs) play an important role in drug therapy and represent one of the largest families o
107 metabolic liver disorders are refractory to drug therapy and require orthotopic liver transplantatio
108 oneedle patches associated with personalized drug therapy and selective toxicity toward specific micr
110 dying disease mechanisms, for development of drug therapies, and for fabrication of tissue equivalent
111 egimens including combination CVD preventive drug therapy, and (4) simplified delivery of healthcare
112 cluded Alzheimer disease drug therapy, other drug therapy, and counseling about safety and future pla
115 dications are initiation, step-up of current drug therapy, and straight substitution of individual dr
118 threats to global health today; conventional drug therapies are becoming increasingly inefficacious a
120 improve adherence to healthy lifestyles and drug therapies are essential and can be implemented at h
125 gh much of their impact can be controlled by drug therapy as with prokaryotic microorganisms, the eme
126 ications and non-steroidal anti-inflammatory drugs therapy) as well as 4 dietary exposures (folate, v
127 -of-care solution for the personalization of drug therapies, as well as for pharmacokinetic studies i
128 ryoballoon ablation than with antiarrhythmic drug therapy, as assessed by continuous cardiac rhythm m
132 ne (I-PTH) is the only FDA approved anabolic drug therapy available for the treatment of osteoporosis
134 investigating complex human diseases and new drug therapies because of their shared genetics and anat
135 provide new evidence of the optimization of drug therapy before percutaneous carotid intervention.
137 ation (CA) when compared with antiarrhythmic drug therapy both as first- and second-line therapy for
139 ndscape of multidrug resistance, alternating-drug therapy can slow evolution by constraining the muta
141 elivery, and the current status of antisense drug therapy clinical trials for gastrointestinal-relate
144 The influences of baseline calcification and drug therapy (dalcetrapib vs. placebo) on progression of
146 lex mutation patterns arising in response to drug therapy despite being disfavored in the wild-type b
151 vides possibilities to fine tune TRPA1-based drug therapies (e.g., for treatment of pain associated w
152 ely to receive rhythm control antiarrhythmic drug therapy, electric cardioversion, or catheter ablati
154 gy-related adverse drug reactions, and multi-drug therapies, especially cancer combination therapy, m
158 heir significant impact on public health, no drug therapies for astrovirus have been identified.
159 ons to eye movements might help in designing drug therapies for human eye movement dysfunctions such
161 revention (P2P) Workshop: Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention to a
162 ilitate the development of new antibacterial drug therapies for treatment of hospital-acquired and ve
166 No significant changes were observed in drug therapy for asthma or their comorbidities nor in th
168 NTS: The Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation trial is an investi
169 ANA (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation) trial randomized 2
170 s associated with traditional small-molecule drug therapy for cancer and to achieve both therapeutic
176 heter ablation is superior to antiarrhythmic drug therapy for maintaining sinus rhythm, but its succe
179 this Series paper, we trace the evolution of drug therapy for osteoporosis, which began in the 1940s
181 ablation as initial therapy was superior to drug therapy for the prevention of atrial arrhythmia rec
182 n group vs 9.2% (n = 101) of patients in the drug therapy group (hazard ratio [HR], 0.86 [95% CI, 0.6
185 en compared with those in the antiarrhythmic drug therapy group (relative risk, 2.04; 95% confidence
186 ble for the catheter ablation group than the drug therapy group at 12 months (5.0 points vs 6.5 point
187 ble for the catheter ablation group than the drug therapy group at 12 months (6.4 points vs 8.1 point
188 able in the catheter ablation group than the drug therapy group at 12 months (86.4 points vs 80.9 poi
189 oints, outcomes in the ablation group vs the drug therapy group, respectively, were 5.2% vs 6.1% for
191 lthough differences between the ablation and drug therapy groups were not statistically significant (
195 mized clinical trial of catheter ablation vs drug therapy in 2204 symptomatic patients with AF older
198 CA seems to be superior to antiarrhythmic drug therapy in drug naive, resistant, and intolerant pa
199 theter ablation was superior to conventional drug therapy in improving all-cause mortality, HF hospit
202 re were differences in the immunosuppressant drug therapy in monotherapy as well as two to three drug
205 Catheter ablation is more effective than drug therapy in restoring sinus rhythm in patients with
206 ding to recommendations for antihypertensive drug therapy in the 2017 ACC/AHA guideline, 2003 Seventh
208 Recently, idebenone has been investigated as drug therapy in the treatment of LHON, although evidence
209 As there is no vaccine and no effective drug therapy in young children for this infection, preve
210 y cited reasons for this absence of specific drug therapies include the heterogeneity of patients wit
211 which can be suppressed through combination drug therapy, including non-obvious drug combinations.
214 s should understand and anticipate potential drug-therapy interactions of targeted temperature manage
225 pulmonary tuberculosis receiving standard 4-drug therapy (isoniazid, rifampin, pyrazinamide, and eth
228 , to provide novel insights into disease and drug therapy mechanisms, and potentially to tailor patie
234 safety and efficacy of a single-dose triple-drug therapy of the antifilarial drugs diethylcarbamazin
235 rove the efficiency of the evaluation of new drug therapies on atherosclerosis and cardiovascular dis
237 lorectal cancer (mCRC), the standard-of-care drug therapies only palliate the symptoms but are ineffe
238 or patients who do not do well with standard drug therapy or for those who prefer a disease-modifying
239 ontrol viral replication in conjunction with drug therapy or in rare cases spontaneously, most antivi
241 s persistence in individuals under effective drug therapy or those who spontaneously control viremia
242 site outcome that included Alzheimer disease drug therapy, other drug therapy, and counseling about s
243 states, such as cancer, and are modulated by drug therapies, our understanding of how such changes sh
245 ntly less in catheter ablation compared with drug-therapy patients across the 5-year follow-up (p < 0
248 rapy, such as drug resistance, combinatorial drug therapy, personalized medicine, and cancer metastas
249 esistance and the restricted pipeline of new drug therapies pose considerable risks to global health
250 lococcus aureus, have received antibacterial drug therapy prior to randomization, and have severe che
253 96 (65%) patients who were on antiarrhythmic drug therapy (relative risk, 0.40; 95% confidence interv
255 anisms of de novo and acquired resistance to drug therapy remains a central challenge in the clinical
258 here was no history of head trauma, surgery, drug therapy, smoking, or alcohol abuse, nor was there a
259 interest to circumvent several obstacles in drug therapy such as rapid drug metabolization, short se
260 eir disease respond poorly to anticonvulsant drug therapy, suggesting a need for new therapeutic targ
261 n blood pressure, adiposity, liver function, drug therapy, symptoms, or quality of life, except that
262 ure is available for OI and to develop novel drug therapies, taking advantage of a repositioning stra
264 use of severe long-term disability yet lacks drug therapies that promote the repair phase of recovery
265 these studies provide a rationale for using drug therapies that restore CD82 expression and inhibit
267 al obstacle, as is the case for any targeted drug therapy that can be developed given the plastic nat
268 netic variation can be used to individualise drug therapy-the topic addressed here-is often viewed as
269 ntricular tachycardia despite antiarrhythmic drug therapy, there was a significantly lower rate of th
270 ese findings open newer avenues for targeted drug therapies, thereby providing hope for the managemen
272 al to reduce adverse effects associated with drug therapy, tissue-specific delivery remains challengi
273 of distant tumor growth and (b) use adjuvant drug therapies to block key identified mediator(s) to su
276 able evidence on long-term (>3 years) use of drug therapies to prevent osteoporotic fractures and ide
278 uld become the targets of future alternative drug therapies to slow down the spread of antibiotic res
280 ults provide proof of principle that a novel drug therapy to treat AKI, and potentially other acute o
281 idence that the AR is a potential target for drug therapy to treat conditions associated with aberran
282 comprehensive analysis, from redirection of drug therapies, to a systematic construction of disease-
283 s for 5 patients with VT storm refractory to drug therapy treated with left stellate ganglion transcu
284 e attractive drug targets for individualized drug therapy trials in the contexts of prevention and tr
286 for determining the sensitivity of tumors to drug therapy, under the assumption that stem cell enrich
288 d treatments across categories (for example, drug therapy vs. weight management) or combined categori
290 stem pharmacology model of TB infection, and drug therapy was developed and used to simulate the outc
292 .5 years), only no treatment or sofosbuvir 3-drug therapy was feasible; for those with long sentences
294 but also accurate diagnostics and monitoring drug therapies, which are critical in clinical and regul
296 lasses may help us understand the actions of drug therapies with selective effects on one population
297 tions for the rational design of combination drug therapies with the potential for synergistic intera
300 e relationship of cardiovascular disease and drug therapy with in-hospital death among hospitalized p